Evidence map›Paper›PMID 40936488›Full record

ArticleChemMedChem2025

Improving the Catalyst Efficiency for Hyperpolarization of Pyruvate Derivatives by Means of Hydrogenative PHIP.

Ginevra Di Matteo, Oksana Bondar, Carla Carrera, Eleonora Cavallari, Sumit Mishra, Francesca Reineri

Abstract read
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ginevra Di MatteoDepartment Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Oksana BondarDepartment Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Carla CarreraNational Research Council (CNR), Institute of Biostructures and Bioimages (IBB), Via Nizza 52, 10126, Torino, Italy.
Eleonora CavallariDepartment Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Sumit MishraDepartment Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
Francesca ReineriDepartment Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.ORCID https://orcid.org/0000-0002-3318-8367

Funding

European Union's Horizon 2020 research and innovation program 766402FETOPEN Program 858149
6 · The paper itself

Abstract

Hyperpolarized pyruvate is the most widely used probe for metabolic imaging in magnetic resonance (MR). Parahydrogen induced polarization- side arm hydrogenation allows to generate it through the catalytic hydrogenation of pyruvate esters. Due to the transient nature of MR hyperpolarization and to the fact that in vivo applications require a high amount of hyperpolarized substrate, a concentrated product solution must be obtained in a few seconds, therefore a high catalyst concentration is needed. The homogeneous rhodium catalyst used for the reaction can be deactivated by the hydrogenation products (or substrates) and the substrate-to-catalyst ratio becomes even lower, especially for pyruvate esters. The addition of tris-phenyl phosphine to the hydrogenation mixture prevents the catalyst deactivation, when it is due to the hydrogenation product allyl pyruvate and the amount of catalyst needed to obtain a concentrated batch of hyperpolarized pyruvate ester has been reduced significantly. Following to hydrolysis and extraction of sodium pyruvate in aqueous phase, the concentration of the hyperpolarized metabolite has been increased to about 60 mM and

Indexed as

PhosphinesPyruvatesPyruvic AcidCatalysisHydrogenationMagnetic Resonance ImagingMolecular StructureRhodiumPhosphinesPyruvatesPyruvic AcidRhodiumhydrogenationhyperpolarizationmagnetic resonance imagingmetabolismpyruvate

Identifiers

PMID40936488
PMCPMC12503905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.